HC Wainwright Reiterates “Buy” Rating for Ardelyx (NASDAQ:ARDX)

HC Wainwright reissued their buy rating on shares of Ardelyx (NASDAQ:ARDX) in a research note released on Friday morning, Benzinga reports. The firm currently has a $11.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2026 earnings at $0.58 EPS.

Other equities analysts also recently issued reports about the stock. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Ardelyx in a research note on Friday, August 2nd. Citigroup lifted their target price on shares of Ardelyx from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, StockNews.com raised Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Ardelyx Price Performance

Shares of ARDX traded up $0.22 during mid-day trading on Friday, reaching $6.09. 8,180,964 shares of the stock traded hands, compared to its average volume of 4,857,587. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -22.55 and a beta of 0.90. Ardelyx has a 1 year low of $3.43 and a 1 year high of $10.13. The firm has a fifty day moving average price of $6.07 and a 200 day moving average price of $6.32. The company has a current ratio of 4.21, a quick ratio of 3.99 and a debt-to-equity ratio of 0.68.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $73.20 million during the quarter, compared to the consensus estimate of $55.03 million. Ardelyx had a negative net margin of 31.02% and a negative return on equity of 39.73%. The firm’s revenue was up 228.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) EPS. As a group, equities research analysts predict that Ardelyx will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael Raab sold 25,000 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $5.91, for a total transaction of $147,750.00. Following the transaction, the chief executive officer now directly owns 1,210,108 shares in the company, valued at approximately $7,151,738.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Michael Raab sold 25,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $5.91, for a total transaction of $147,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,210,108 shares in the company, valued at $7,151,738.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Justin A. Renz sold 5,289 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $5.86, for a total transaction of $30,993.54. Following the sale, the chief financial officer now owns 295,257 shares in the company, valued at approximately $1,730,206.02. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 212,126 shares of company stock worth $1,298,963 in the last 90 days. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

Large investors have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its position in Ardelyx by 1,026.3% during the second quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 3,233 shares during the period. Redwood Wealth Management Group LLC bought a new position in Ardelyx during the second quarter worth $62,000. Coastal Bridge Advisors LLC acquired a new stake in Ardelyx during the second quarter worth about $74,000. Helen Stephens Group LLC bought a new stake in shares of Ardelyx in the 3rd quarter worth approximately $76,000. Finally, Paloma Partners Management Co bought a new position in shares of Ardelyx during the first quarter worth about $86,000. 58.92% of the stock is owned by hedge funds and other institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.